title: Statins and stroke prevention.
abstract: Over the past decade, statins have been proven to significantly decrease coronary events in primary and secondary prevention of coronary artery disease. Recent clinical trials have indicated that statins significantly reduce stroke risk in patients with vascular disease. The Cholesterol Treatment Trialists' Collaborators in a meta-analysis including 90,056 patients found that the use of statins determined a significant 17% proportional reduction in the incidence of first-ever stroke of any type per 1 mmol/l low-density lipoprotein (LDL) cholesterol reduction. During an average of 5 years of treatment, the reduction in the overall incidence of stroke was about one sixth per 1 mmol/l LDL cholesterol decrease meaning that 8 fewer participants have any stroke per 1,000 among those with preexisting coronary artery disease at baseline, compared with 5 fewer per 1,000 among the participants with no such history. It is not known whether these findings might be due to the cholesterol reduction effect of statins or to pleiotropic effects of statins, such as improved endothelial function, decreased platelet aggregability, and reduced vascular inflammation. In secondary prevention of stroke, the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study found that treatment with atorvastatin reduced the risk of recurrent cerebrovascular events in patients with recent stroke or transient ischemic attack but no history of heart disease. Combining the results of patients with no history of heart disease from the SPARCL study and Heart Protection Study in a mini meta-analysis, compared with placebo, statins were associated with a barely nonsignificant difference in recurrent stroke (OR = 0.87, 95% CI = 0.75-1.01, p = 0.07) and a significant difference in the occurrence of major vascular events (OR = 0.78, 95% CI = 0.68-0.88, p = 0.0001) at final follow-up.
authors.affiliation: Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Perugia, Italy. maurizio.paciaroni@med.unipg.it
authors.forename: Maurizio
authors.initials: M
authors.lastname: Paciaroni
authors.forename: Michael
authors.initials: M
authors.lastname: Hennerici
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Agnelli
authors.forename: Julien
authors.initials: J
authors.lastname: Bogousslavsky
mesh_terms: D050197:Atherosclerosis / Q000150:complications / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D002339:Carotid Arteries / Q000473:pathology; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016017:Odds Ratio; D017410:Practice Guidelines as Topic; D012107:Research Design; D018570:Risk Assessment; D012307:Risk Factors; D055502:Secondary Prevention; D020521:Stroke / Q000097:blood / Q000209:etiology* / Q000517:prevention & control*; D016896:Treatment Outcome; D017539:Tunica Intima / Q000473:pathology; D017540:Tunica Media / Q000473:pathology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol